The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 351:2489-2497 December 9, 2004 Number 24
NextNext

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
Peter G. Rose, M.D., Stacy Nerenstone, M.D., Mark F. Brady, Ph.D., Daniel Clarke-Pearson, M.D., George Olt, M.D., Stephen C. Rubin, M.D., David H. Moore, M.D., James M. Small, M.D., Ph.D., for the Gynecologic Oncology Group

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
by Thigpen, T.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival and overall survival among patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary surgery.

Methods Women were enrolled within six weeks after primary surgery. If, after three cycles of postoperative paclitaxel plus cisplatin, a patient had no evidence of progressive disease, she was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of chemotherapy or three more cycles of chemotherapy alone.

Results We enrolled 550 women. After completing three cycles of postoperative chemotherapy, 216 eligible patients were randomly assigned to receive secondary surgical cytoreduction followed by chemotherapy and 208 to receive chemotherapy alone. Surgery was declined by or medically contraindicated in 15 patients who were assigned to secondary surgery (7 percent). As of March 2003, 296 patients had died and 82 had progressive disease. The likelihood of progression-free survival in the group assigned to secondary surgery plus chemotherapy, as compared with the chemotherapy-alone group, was 1.07 (95 percent confidence interval, 0.87 to 1.31; P=0.54), and the relative risk of death was 0.99 (95 percent confidence interval, 0.79 to 1.24; P=0.92).

Conclusions For patients with advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplatin does not improve progression-free survival or overall survival.


Source Information

From Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center — both in Cleveland (P.G.R.); the Department of Medicine, University of Connecticut, and Hartford Hospital — both in Hartford (S.N.); the Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, N.Y. (M.F.B.); the Division of Gynecologic Oncology, Duke University Medical Center, Durham, N.C. (D.C.-P.); the Division of Gynecologic Oncology, Pennsylvania State University, Hershey Medical Center, Hershey (G.O.); the Division of Gynecologic Oncology, University of Pennsylvania Cancer Center, Philadelphia (S.C.R.); the Division of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis (D.H.M.); and UniPath and Colorado Gynecologic Oncology — both in Denver (J.M.S.).

Address reprint requests to Ms. Denise Mackey at the Gynecologic Oncology Group Administrative Office, 4 Penn Center, 1600 JFK Blvd., Suite 1020, Philadelphia, PA 19103.

Full Text of this Article


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.